3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Leukemia stem cells (LSCs) promote the disease and seem resistant to therapy and immune control. Why LSCs are selectively resistant against elimination by CD8 + cytotoxic T cells (CTLs) is still unknown. In this study, we demonstrate that LSCs in chronic myeloid leukemia (CML) can be recognized and killed by CD8 + CTLs in vitro. However, Tregs, which preferentially localized close to CD8 + CTLs in CML BM, protected LSCs from MHC class I–dependent CD8 + CTL–mediated elimination in vivo. BM Tregs in CML were characterized by the selective expression of tumor necrosis factor receptor 4 (Tnfrsf4). Stimulation of Tnfrsf4 signaling did not deplete Tregs but reduced the capacity of Tregs to protect LSCs from CD8 + CTL–mediated killing. In the BM of newly diagnosed CML patients, TNFRSF4 mRNA levels were significantly increased and correlated with the expression of the Treg-restricted transcription factor FOXP3. Overall, these results identify Tregs as key regulators of immune escape of LSCs and TNFRSF4 as a potential target to reduce the function of Tregs and boost antileukemic immunity in CML.

          Abstract

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

          Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data capture tools to support clinical and translational research. We present: (1) a brief description of the REDCap metadata-driven software toolset; (2) detail concerning the capture and use of study-related metadata from scientific research teams; (3) measures of impact for REDCap; (4) details concerning a consortium network of domestic and international institutions collaborating on the project; and (5) strengths and limitations of the REDCap system. REDCap is currently supporting 286 translational research projects in a growing collaborative network including 27 active partner institutions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Signatures of mutational processes in human cancer

            All cancers are caused by somatic mutations. However, understanding of the biological processes generating these mutations is limited. The catalogue of somatic mutations from a cancer genome bears the signatures of the mutational processes that have been operative. Here, we analysed 4,938,362 mutations from 7,042 cancers and extracted more than 20 distinct mutational signatures. Some are present in many cancer types, notably a signature attributed to the APOBEC family of cytidine deaminases, whereas others are confined to a single class. Certain signatures are associated with age of the patient at cancer diagnosis, known mutagenic exposures or defects in DNA maintenance, but many are of cryptic origin. In addition to these genome-wide mutational signatures, hypermutation localized to small genomic regions, kataegis, is found in many cancer types. The results reveal the diversity of mutational processes underlying the development of cancer with potential implications for understanding of cancer etiology, prevention and therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              QuPath: Open source software for digital pathology image analysis

              QuPath is new bioimage analysis software designed to meet the growing need for a user-friendly, extensible, open-source solution for digital pathology and whole slide image analysis. In addition to offering a comprehensive panel of tumor identification and high-throughput biomarker evaluation tools, QuPath provides researchers with powerful batch-processing and scripting functionality, and an extensible platform with which to develop and share new algorithms to analyze complex tissue images. Furthermore, QuPath’s flexible design makes it suitable for a wide range of additional image analysis applications across biomedical research.
                Bookmark

                Author and article information

                Contributors
                Journal
                JCI Insight
                JCI Insight
                JCI Insight
                JCI Insight
                American Society for Clinical Investigation
                2379-3708
                8 December 2021
                8 December 2021
                8 December 2021
                : 6
                : 23
                : e151797
                Affiliations
                [1 ]Department of Medical Oncology, Inselspital, Bern University Hospital,
                [2 ]Department for BioMedical Research (DBMR),
                [3 ]Graduate School of Cellular and Biomedical Sciences, and
                [4 ]Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland.
                Author notes
                Address correspondence to: Carsten Riether, Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland. Phone: 41.31.632.0956; Email: carsten.riether@ 123456insel.ch .

                Authorship note: MH and VR contributed equally to this work.

                Author information
                http://orcid.org/0000-0002-4779-4296
                http://orcid.org/0000-0003-3008-3268
                http://orcid.org/0000-0002-5632-7833
                http://orcid.org/0000-0003-1773-5436
                http://orcid.org/0000-0001-7512-513X
                Article
                151797
                10.1172/jci.insight.151797
                8675189
                34727093
                dc04e7c3-ae7a-4f67-88e6-12ba609cff7c
                © 2021 Hinterbrandner et al.

                This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 May 2021
                : 27 October 2021
                Funding
                Funded by: Swiss National Science Foundation
                Award ID: 310030_179394
                Categories
                Research Article

                hematology,stem cells,cancer immunotherapy,leukemias
                hematology, stem cells, cancer immunotherapy, leukemias

                Comments

                Comment on this article